• Curasight posted a Q2 operating loss of DKK 11.49 million, narrowing 39.54% year over year.
• Loss for the period narrowed 40.51% to DKK 11.43 million; earnings per share improved to DKK -0.24.
• Total assets rose to DKK 56.08 million; equity ratio fell 40.5 percentage points to 27.1%.
• Directed share issue raised about DKK 20 million, strengthening the financial position.
• Topline uTREAT Phase 1 glioblastoma data seen in H1 2027; uTRACE Phase 2 prostate cancer data also expected in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curasight A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260826:BIT:2772:0) on August 27, 2026, and is solely responsible for the information contained therein.